In addition, we have shown that miR-15a inhibits the previously described targets BCL2 and BMI1 in colon cancer as well as novel targets, YAP1, a transcriptional coactivator and oncogene and DCLK1, a colon CSC marker [22–27]. Here, BCL2 is linked to malignant colon neoplasm.